Roche/Genentech will join Parent Project Muscular Dystrophy for a webinar on Wednesday, May 16 at 1:00 PM EDT to provide an update on their Anti-Myostatin Adnectin (RG6206) development program.

You will learn more about the team at Roche and its US affiliate, Genentech, and how they are collaborating with the Duchenne community. The team will also update you on their Anti-Myostatin Adnectin (RG6206) program, including the status of ongoing clinical studies.

For additional information regarding the RG6206 studies please visit clinicaltrials.gov (NCT03100630, NCT02515669, NCT03039686) or www.roche-duchenne-clinicaltrials.com.

Moderator:

• Pat Furlong
  Founding President & CEO
  Parent Project Muscular Dystrophy

Presenters:

• Sangeeta Jethwa
  Head, Patient Partnership, Rare Diseases, Basel, Switzerland
  Roche Switzerland

• Michelle Krishnan
  Translational Medicine Leader, Basel, Switzerland
  Roche Switzerland

• J.P. Sacksteder
  Alliance & Advocacy Relations, Government Affairs, San Francisco
  Genentech

• Michael Solomonides
  Operations Program Leader, UK
  Roche UK

Please submit questions in advance to info@parentprojectmd.org (subject line: Roche/Genentech Webinar) by Monday, May 14 at 12pm eastern.

Register Now >